Uncover key drivers, emerging technologies, and competitive movements shaping the hepatorenal syndrome market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Hepatorenal Syndrome Market in 2026, and what figure is it projected to hit by 2030?

The hepatorenal syndrome market size has experienced substantial growth in recent years. It is anticipated to increase from $1.37 billion in 2025 to $1.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. This historical growth can be attributed to the rising prevalence of chronic liver disease, an increasing incidence of complications related to cirrhosis, the expansion of intensive care unit infrastructure, enhanced clinical awareness of HRS diagnosis, and the availability of vasoconstrictor-based therapies.

The market for hepatorenal syndrome is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $1.91 billion by 2030, progressing at a compound annual growth rate (CAGR) of 6.9%. This projected growth during the forecast period stems from factors such as an increase in liver transplant procedures, a heightened emphasis on identifying HRS in its early stages, the proliferation of sophisticated renal support treatments, the increasing integration of precision medicine strategies, and greater financial commitment to clinical research concentrated on hepatology. Key developments anticipated in the forecast period encompass a wider acceptance of targeted vasoconstrictor treatments, an expanded application of early diagnostic biomarkers, a stronger emphasis on comprehensive multidisciplinary critical care management, an increase in albumin-based combination therapies, and improved surveillance of kidney function among individuals with liver disease.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22001&type=smp

Which Drivers Are Affecting Market Participation In The Hepatorenal Syndrome Market?

The growing occurrence of liver ailments is anticipated to fuel the expansion of the hepatorenal syndrome market in the future. Liver diseases encompass conditions that compromise liver function, such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases. The rise in these conditions stems from factors like obesity, diabetes, alcohol consumption, viral infections, inadequate nutrition, and exposure to toxins. The escalating prevalence of liver diseases, including cirrhosis and acute liver failure, heightens the likelihood of hepatorenal syndrome (HRS) by inducing severe hemodynamic and kidney dysfunction resulting from advancing liver impairment. For example, in April 2024, the Office for Health Improvement & Disparities (OHID), a UK government department, indicated that UK hospital admissions for liver disease climbed to 155.2 per 100,000 in 2023, an increase from 150.6 per 100,000 in 2022. Consequently, the increasing incidence of liver diseases is propelling the growth of the hepatorenal syndrome market.

Hepatorenal Syndrome Market Driver: Increase In Research And Development Investments Driving The Growth Of The Market Due To Advancements In Therapies And Diagnostics

What Segment Categories Are Covered In The Hepatorenal Syndrome Market?

The hepatorenal syndrome market covered in this report is segmented –

1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, Other Types

2) By Treatment: Liver Transplantation, Terlipressin Infusion, Albumin Infusion, Hemodialysis, Vasoconstrictors

3) By Diagnosis: Liver Function Tests, Urinalysis And Urine Electrolytes, Other Diagnoses

4) By End Users: Hospitals, Specialty Clinics

Subsegments:

1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS, Rapidly Progressive Renal Failure

2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS, Slowly Progressive Renal Failure

3) By Other Types: HRS With Cirrhosis, HRS With Acute Liver Failure, HRS With Alcoholic Hepatitis

What Upcoming Trends Are Likely To Define The Future Path Of The Hepatorenal Syndrome Market?

Major companies operating in the hepatorenal syndrome market are focusing on developing innovative devices, such as cytopheretic devices, to improve patient outcomes by reducing inflammation, stabilizing kidney function, and enhancing treatment effectiveness for Hepatorenal Syndrome (HRS). The cytopheretic device (Cytosorb) is an extracorporeal blood purification therapy designed to reduce systemic inflammation and immune activation in critically ill patients, including those with Hepatorenal Syndrome (HRS). For instance, in October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, received FDA approval for its Selective Cytopheretic Device (SCD) for the treatment of hepatorenal syndrome (HRS). This advanced, cell-directed therapy targets hyperinflammation, a key driver of kidney dysfunction in patients with acute-on-chronic liver failure. By leveraging immunomodulation, SCD helps regulate abnormal immune responses, potentially supporting kidney recovery and improving patients’ eligibility for life-saving liver transplants. Its effectiveness in enhancing solid organ function has been demonstrated in preclinical and clinical studies across conditions such as sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

Which Major Industry Participants Are Leading The Hepatorenal Syndrome Market Growth?

Major companies operating in the hepatorenal syndrome market are Eli Lilly and Company, Baxter International Inc., Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Ltd, La Jolla Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc., Innoviva Specialty Therapeutics Inc, BioVie Inc., SeaStar Medical, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb, Novartis AG, Sanofi, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Bayer AG, AstraZeneca

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Hepatorenal Syndrome Market?

North America was the largest region in the hepatorenal syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hepatorenal Syndrome Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22001&type=smp

Browse Through More Reports Similar to the Global Hepatorenal Syndrome Market 2026, By The Business Research Company

Heparin Market Report 2026

https://www.thebusinessresearchcompany.com/report/heparin-global-market-report

Hepatic Encephalopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Dumping Syndrome Market Report 2026

https://www.thebusinessresearchcompany.com/report/dumping-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model